- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:00 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.01.2026 | 200 | Xetra Newsboard | Das Instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG KG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 12.01.2026 und ex Kapitalmassnahme am 13.01.2026 The instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG... ► Artikel lesen | |
| 18.11.25 | Lytix Biopharma Q3 2025 slides: Ruxotemitide advances as cash runway extends to 2026 | 2 | Investing.com | ||
| 18.11.25 | LYTIX BIOPHARMA AS: Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy | 2 | Cision News | ||
| 14.11.25 | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q3 2025 Results Presentation | 1 | Cision News | ||
| 11.11.25 | LYTIX BIOPHARMA AS: Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital | 1 | Cision News | ||
| 10.11.25 | LYTIX BIOPHARMA AS: New Phase II Study Data from Lytix Biopharma's Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide | 1 | Cision News | ||
| LYTIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 10.10.25 | Lytix Biopharma AS: Financial calendar | - | Oslo Børs | ||
| 08.10.25 | LYTIX BIOPHARMA AS: Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 | 3 | Cision News | ||
| 01.09.25 | Lytix Biopharma AS: Grant of share options to management and key personnel | 1 | Cision News | ||
| 28.08.25 | Lytix Biopharma Q2 2025: Krebstherapie auf dem Weg in Phase III bei verbesserter Finanzlage | 3 | Investing.com Deutsch | ||
| 28.08.25 | Lytix Biopharma Q2 2025 slides: advancing cancer therapy toward Phase III with improved financials | 1 | Investing.com | ||
| 28.08.25 | LYTIX BIOPHARMA AS: Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization | 1 | Cision News | ||
| 21.08.25 | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q2 2025 Results Presentation | 1 | Cision News |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 288,45 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| CG ONCOLOGY | 54,20 | 0,00 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| ALUMIS | 19,560 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 28,080 | 0,00 % | Piper Sandler startet Coverage für Olema Pharmaceuticals mit "Overweight" und sieht deutliches Potenzial | ||
| ARCELLX | 66,27 | 0,00 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| ENLIVEN THERAPEUTICS | 26,000 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,500 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,37 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,350 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,060 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,810 | 0,00 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| NUVALENT | 105,05 | 0,00 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,950 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| NURIX THERAPEUTICS | 19,300 | 0,00 % | What 18 Analyst Ratings Have To Say About Nurix Therapeutics | ||
| MONTE ROSA THERAPEUTICS | 24,310 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen |
Das Unternehmen LYTIX BIOPHARMA AS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,008 (+1,03 %) liegt der Kurs bei 0,782 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYTIX BIOPHARMA AS finden Sie auf Wallstreet Online.